An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

Subjects who suffer from migraine attacks.

Subject has confirmed or suspected ischemic heart disease; angina pectoris, history of myocardial infarction, documented silent ischemia, Prinzmetal's angina-coronary vasospasm, signs, or symptoms consistent with any of the above.

Subject has evidence or history of ischemic abdominal syndromes, peripheral vascular disease or Raynaud's syndrome.

Subject has cardiac arrhythmias requiring medication or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study.

Subject has a history of cerebrovascular pathology including stroke and/or transient ischemic attacks.

Subject has a history of congenital heart disease.

Subject has hypertension at screening.

Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease.

Subject has a history of epilepsy or structural brain lesions which lower the convulsive threshold or treated with an antiepileptic drug for seizure control within 5 years prior to screening.

History of impaired hepatic or renal function.

Subject is currently taking or has taken in the previous 4 weeks, herbal preparations containing St. John's Wort.

Use of other prescription or non-prescription drugs, vitamins, herbal and dietary supplements, within 7 days prior to the first dose of study medication.

Note: Excluded from this list are: acetaminophen at doses of less than or equal to 2 grams per day and contraceptives.

Subject has a hypersensitivity, intolerance, or contraindication to the use of sumatriptan or naproxen sodium or any of their components or any other 5-HT1 receptor agonist.

Subject has a history of any gastrointestinal surgery that specifically indicates a past history of bleeding, ulceration or perforation.

Subject has a history of gastric bypass or stapling surgery.

Subject has a history of GI ulceration in the past six months or gastrointestinal bleeding in the past year.

Subject has a history of inflammatory bowel disease.

Treatment with an investigational drug within 30 preceding the first dose of study medication.

Positive serum beta-human chorionic gonadotropin test -females.

Pregnant, actively trying to become pregnant or breast-feeding.

Subjects with a history of drug or alcohol abuse.

History of regular alcohol consumption exceeding 7 drinks per week for females or 14 drinks per week for men within 6 months of screening.

Positive urine drug screen including alcohol at screening.

Donation of blood in excess of 500 mL within 56 days prior to first dose of study medication.

Subjects who smoke more than 10 cigarettes per day.

History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to any of the study medications or components thereof.

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

What this study is about

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

What this study is about